Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results
Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.
How this was made
The 30-second read
Why it matters
The combination of a new FDA approval, first product sales, and a strong analyst rating creates a fresh positive catalyst for the stock.
Market read
The news provides a new, material catalyst for SRRK, likely prompting short‑term buying interest.
What to watch
Potential reimbursement challenges for the J‑code and limited commercial scale in early 2027.
Background
Scholar Rock reported Q3 2026 earnings with a modest EPS beat but a significant revenue shortfall, while announcing FDA approval for its SMA drug ISEMBYLD and first product revenues.
Ticker impact
Raymond James reiterated a Strong Buy rating and posted a $72 price target after Scholar Rock's Q3 2026 earnings and FDA approval of ISEMBYLD, its first product revenue.
upward pressure as investors price in the new product launch and higher target.
First FDA approval and first product revenue are material for a biotech; analyst rating reinforces bullish outlook.
Market effects
May lift other small‑cap biotech stocks awaiting FDA approvals.
Positive for US biotech sector in the near term.
Limited to biotech investors; no broad market effect.
Counterpoint
Revenue miss and small scale could limit upside; watch for execution risk on launch.
Key entities
- companyScholar Rock
Biotech firm developing SMA therapy ISEMBYLD.
- analyst_firmRaymond James
Reiterated Strong Buy rating and $72 price target.
